Sign In
Buy SNN
Smith & Nephew SNATS Earnings Calls
| Release date | Mar 02, 2026 |
| EPS estimate | $1.16 |
| EPS actual | $1.18 |
| EPS Surprise | 1.72% |
| Revenue estimate | 2.774B |
| Revenue actual | 3.203B |
| Revenue Surprise | 15.48% |
| Release date | Aug 05, 2025 |
| EPS estimate | $0.86 |
| EPS actual | $0.672 |
| EPS Surprise | -21.68% |
| Revenue estimate | 1.509B |
| Revenue actual | 2.988B |
| Revenue Surprise | 98.04% |
| Release date | Jul 30, 2025 |
| EPS estimate | - |
| EPS actual | - |
| Revenue estimate | - |
| Revenue actual | - |
| Release date | Feb 25, 2025 |
| EPS estimate | $0.92 |
| EPS actual | $0.225 |
| EPS Surprise | -75.53% |
| Revenue estimate | 1.522B |
| Revenue actual | 2.983B |
| Revenue Surprise | 96.03% |
Last 4 Quarters for Smith & Nephew SNATS
Below you can see how SNN performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 25, 2025 |
| Price on release | $28.11 |
| EPS estimate | $0.92 |
| EPS actual | $0.225 |
| EPS surprise | -75.53% |
| Date | Price |
|---|---|
| Feb 19, 2025 | $25.62 |
| Feb 20, 2025 | $25.72 |
| Feb 21, 2025 | $26.13 |
| Feb 24, 2025 | $26.28 |
| Feb 25, 2025 | $28.11 |
| Feb 26, 2025 | $28.92 |
| Feb 27, 2025 | $28.98 |
| Feb 28, 2025 | $28.96 |
| Mar 03, 2025 | $29.65 |
| 4 days before | 9.72% |
| 4 days after | 5.48% |
| On release day | 2.88% |
| Change in period | 15.73% |
| Release date | Jul 30, 2025 |
| Price on release | $30.93 |
| EPS estimate | - |
| EPS actual | - |
| Date | Price |
|---|---|
| Jul 24, 2025 | $31.48 |
| Jul 25, 2025 | $31.67 |
| Jul 28, 2025 | $31.18 |
| Jul 29, 2025 | $31.60 |
| Jul 30, 2025 | $30.93 |
| Jul 31, 2025 | $30.56 |
| Aug 01, 2025 | $30.83 |
| Aug 04, 2025 | $30.79 |
| Aug 05, 2025 | $35.48 |
| 4 days before | -1.75% |
| 4 days after | 14.71% |
| On release day | -1.20% |
| Change in period | 12.71% |
| Release date | Aug 05, 2025 |
| Price on release | $35.48 |
| EPS estimate | $0.86 |
| EPS actual | $0.672 |
| EPS surprise | -21.68% |
| Date | Price |
|---|---|
| Jul 30, 2025 | $30.93 |
| Jul 31, 2025 | $30.56 |
| Aug 01, 2025 | $30.83 |
| Aug 04, 2025 | $30.79 |
| Aug 05, 2025 | $35.48 |
| Aug 06, 2025 | $35.50 |
| Aug 07, 2025 | $36.08 |
| Aug 08, 2025 | $36.14 |
| Aug 11, 2025 | $35.96 |
| 4 days before | 14.71% |
| 4 days after | 1.35% |
| On release day | 0.0564% |
| Change in period | 16.26% |
| Release date | Mar 02, 2026 |
| Price on release | $35.76 |
| EPS estimate | $1.16 |
| EPS actual | $1.18 |
| EPS surprise | 1.72% |
| Date | Price |
|---|---|
| Feb 24, 2026 | $35.97 |
| Feb 25, 2026 | $36.29 |
| Feb 26, 2026 | $36.68 |
| Feb 27, 2026 | $36.90 |
| Mar 02, 2026 | $35.76 |
| Mar 03, 2026 | $36.75 |
| Mar 04, 2026 | $36.36 |
| Mar 05, 2026 | $34.85 |
| Mar 06, 2026 | $34.31 |
| 4 days before | -0.584% |
| 4 days after | -4.05% |
| On release day | 2.77% |
| Change in period | -4.61% |
Smith & Nephew SNATS Earnings Call Transcript Summary of Q4 2025
Smith & Nephew finished FY25 strongly, delivering underlying revenue growth of 5.3% with all three business units >5% growth, 160 bps trading margin expansion to 19.7%, and free cash flow of $840m (up 52.5%), enabling completion of a $500m buyback. Growth was broad-based: Orthopaedics accelerated (notably Hips, Trauma & Extremities and CORI robot adoption), Sports Medicine & ENT reached >$1bn in Joint Repair driven by REGENETEN and Q-FIX, and Advanced Wound Management showed momentum in AWD/Bioactives and early traction for ALLEVYN COMPLETE CARE. Over 60% of 2025 growth came from products launched in the last five years. The company has realized substantial efficiency savings under its 12-Point Plan and plans further gains via Ortho360. For 2026 management guides to ~6% organic revenue growth and ~8% organic trading profit growth (and around $1.3bn trading profit including the recently announced Integrity Orthopaedics acquisition). Key near-term headwinds flagged: China VBP (largely annualized), tariffs, CMS wound reimbursement changes, inventory revaluation and some one-off restructuring as manufacturing network is optimized. Mid-term RISE targets: 6–7% organic revenue CAGR, 9–10% trading profit CAGR, >$1bn free cash flow by 2028 and 12–13% ROIC.
